Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: An oral cavity care method uses a fine ozone bubble liquid, wherein a stock solution of the fine ozone bubble liquid has ozone gas concentration of 100 ppm or more, even if ozone gas concentration of the fine ozone bubble liquid is diluted to 4 ppm or less, the fine ozone bubble liquid has a sterilizing action, the fine ozone bubble liquid has ozone gas concentration of 4 ppm or more after frozen storage for one year or more, and in addition to the sterilizing action, the fine ozone bubble liquid has an odor component decomposition action and an antiviral action.

Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

Abstract: Provided is an oral care composition and methods of making and using the same. The composition may include an orally acceptable vehicle, including pectin in an amount of from about 0.1% to about 1% by weight, an anticaries agent; and a moisturizing agent.

Abstract: In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 2 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.

Abstract: Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and commercial manufacturing processes for making bupivacaine MVLs.

Abstract: Delivery of compositions for treatment of skin tissue with photoactive plasmonic nanoparticles and light, with embodiments relating to delivery devices. Treatments are useful for cosmetic, diagnostic and therapeutic applications.

Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.

Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.

Abstract: Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.

Abstract: The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system.

Abstract: There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.

Abstract: The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Abstract: A bioactive glass composition including: 50 to 70% SiO2; 0.1 to 10% Al2O3, 5 to 30% Na2O, 0.1 to 15% K2O, 0.1 to 15% MgO, 0.1 to 20% CaO, and 5 to 10% P2O5, based on a 100 wt % of the composition. Also disclosed is a method of making the bioactive glass composition.

Abstract: The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system.

Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Abstract: An antimicrobial composition with a synergistic combination of ingredients is described. Cosmetic compositions containing the antimicrobial composition with improved preservation properties are also described. The cosmetic compositions are effective in treating the skin to cleanse, moisturize and to reduce the effects of aging and photo damage and treat other skin conditions after being topically applied.

Abstract: The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).